Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05761392

APP-based Precise Management System of Chronic Intractable Pain

The goal of this clinical trial is to learn about a new management system in chronic and stubborn pain patients who accept therapy of spinal cord stimulation (SCS). Usually, these patients are required to take long-term follow-ups to ensure that the stimulator works well. The main questions it aims to answer are:

* Is it better to improve the patient's quality of life than the current conventional follow-up? * Is it better to relieve pain in the long term than the current conventional follow-up? * Is it possible to be applied to a large population of chronic pain patients? Participants will be randomly assigned to either a control group or an interventional group.

Participants in the control group will be given the standard SCS implantation surgery and asked to complete the conventional follow-up (at least 1-, 3-, and 6-month post-operative).

Participants in the interventional group will be given the standard SCS implantation surgery and asked to do the following things:

* Take the daily pain self-assessment questions on a mobile phone APP. * Take the monthly healthy status self-assessment questionnaires on a mobile phone APP. * Take the conventional follow-up (at least 1-, 3-, and 6-month post-operative). Researchers will compare the two groups to see if the life quality of the interventional group is improved.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Chronic intractable pain is a disorder with complicated causes. The patient's quality of life is significantly reduced as a result of the patient's ongoing discomfort and the necessity for lengthy therapies. When patients don't respond well to medicine or other non-surgical treatments, spinal cord stimulation (SCS) is one of the surgical methods employed. The safety and effectiveness of SCS have previously been confirmed in numerous trials as a well-researched and clinically used therapy. However, the adjustment of SCS is complicated and its optimal effect relies on long-term regular follow-up. With the development of the internet, the investigators put forward a new system with remote and wireless SCS devices. Together with an exclusively developed mobile phone application, patients will be able to record their daily pain state and monthly health condition and make customized stimulation settings accordingly. This study is aimed to test the feasibility of this new precise management system. All participants will be randomly assigned to either interventional or control group. Participants in control group will be asked to take the conventional follow-up. Participants in interventional group will be additionally asked to take self-assessment on daily pain state and monthly health condition. The investigators hypothesized that this self-involved, closely monitored, and precisely adjusted system can significantly improve patients' quality of life in the long term and cut down both the financial expenses and time cost.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have been clinically diagnosed with chronic, intractable pain for more than three months.
  • At enrollment, the average pain intensity is no least than 5 out of 10 cm on visual analogue scale.
  • At enrollment, the age is no younger than 18-year-old.
  • Ineffective or unsatisfactory conservative treatments, including but limited to: oral medication, nerve block, epidural corticosteroids, physical and psychological rehabilitation therapy, and chiropractic care.
  • Voluntary to take the trial and sign the informed consent.
  • Good compliance and ability to complete post-operative follow-ups.
  • Basic ability to read and use a mobile phone or having a caregiver who can.

Exclusion criteria

  • Bleeding complications or coagulation disorders.
  • Mental or cognitive disorders leading to inability to complete implantation surgery or post-operative follow-up.
  • Issues with spinal cord or vertebrates that are not suitable for implantation surgery.
  • Systemic active infections or local infections around the surgery area.
  • Pregnancy, breast-feeding, plan to be pregnant or unwilling to use contraceptive methods.
  • Metastatic malignant tumors or untreated malignant tumors.
  • Life expectancy of less than one year.
  • Already provided with a medication pump and/or other implanted devices.
  • Need for therapy or examination that must not have an implanted pulse generator (IPG), such as magnetic resonance imaging (MRI) and thermo-therapy.
  • Heavily addicted to alcohol or drugs.
  • VAS improvement less than 50% or stimulation intolerance during the test period.
  • Unable to complete long-term online follow-ups because of hardware issues such as internet, mobile phones, and so on.
  • Unwilling to participate.
  • Other inappropriate situations determined by the investigators.

Treatment and study plan

Precise management

Other

The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.

Primary outcomes

  1. Health Condition and Life Quality: Change From Baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) utility values at Month 1

    Time frame: Baseline and Month 1

    Participants' health condition and life quality are measured by EQ-5D-5L utility values. EQ-5D-5L utility value has a minimum of 0 and a maximum of 1. Higher values mean a better health condition.

  2. Health Condition and Life Quality: Change From Baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) utility values at Month 3

    Time frame: Baseline and Month 3

    Participants' health condition and life quality are measured by EQ-5D-5L utility values. EQ-5D-5L utility value has a minimum of 0 and a maximum of 1. Higher values mean a better health condition.

  3. Health Condition and Life Quality: Change From Baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) utility values at Month 6

    Time frame: Baseline and Month 6

    Participants' health condition and life quality are measured by EQ-5D-5L utility values. EQ-5D-5L utility value has a minimum of 0 and a maximum of 1. Higher values mean a better health condition.

Secondary outcomes

  1. Pain Intensity: Change From Baseline in Visual Analogue Scale (VAS) at Month 1

    Time frame: Baseline and Month 1

    Pain intensity is assessed by VAS and compared with baseline VAS score. VAS has a minimum of 0 and a maximum of 10. Higher values mean a stronger pain.

  2. Pain Intensity: Change From Baseline in Visual Analogue Scale (VAS) at Month 3

    Time frame: Baseline and Month 3

    Pain intensity is assessed by VAS and compared with baseline VAS score. VAS has a minimum of 0 and a maximum of 10. Higher values mean a stronger pain.

  3. Pain Intensity: Change From Baseline in Visual Analogue Scale (VAS) at Month 6

    Time frame: Baseline and Month 6

    Pain intensity is assessed by VAS and compared with baseline VAS score. VAS has a minimum of 0 and a maximum of 10. Higher values mean a stronger pain.

  4. Pain Time: Change From Baseline in Time-Intensity Curve at Month 1

    Time frame: Baseline and Month 1

    Temporal characteristics of pain is assessed by a time-intensity curve and compared with baseline curve.

  5. Pain Time: Change From Baseline in Time-Intensity Curve at Month 3

    Time frame: Baseline and Month 3

    Temporal characteristics of pain is assessed by a time-intensity curve and compared with baseline curve.

  6. Pain Time: Change From Baseline in Time-Intensity Curve at Month 6

    Time frame: Baseline and Month 6

    Temporal characteristics of pain is assessed by a time-intensity curve and compared with baseline curve.

  7. Pain Location: Change From Baseline in Pain Map at Month 1

    Time frame: Baseline and Month 1

    Spatial characteristics of pain is assessed by a pain map and compared with baseline pain map.

  8. Pain Location: Change From Baseline in Pain Map at Month 3

    Time frame: Baseline and Month 3

    Spatial characteristics of pain is assessed by a pain map and compared with baseline pain map.

  9. Pain Location: Change From Baseline in Pain Map at Month 6

    Time frame: Baseline and Month 6

    Spatial characteristics of pain is assessed by a pain map and compared with baseline pain map.

  10. Health condition: Change From Baseline in EuroQol Visual Analogue Scale (EQ VAS) at Month 1

    Time frame: Baseline and Month 1

    Overall health condition is assessed by EQ VAS and compared with baseline EQ VAS. EQ VAS has a minimum of 0 and a maximum of 100. Higher scores mean a better health condition.

  11. Health condition: Change From Baseline in EuroQol Visual Analogue Scale (EQ VAS) at Month 3

    Time frame: Baseline and Month 3

    Overall health condition is assessed by EQ VAS and compared with baseline EQ VAS. EQ VAS has a minimum of 0 and a maximum of 100. Higher scores mean a better health condition.

  12. Health condition: Change From Baseline in EuroQol Visual Analogue Scale (EQ VAS) at Month 6

    Time frame: Baseline and Month 6

    Overall health condition is assessed by EQ VAS and compared with baseline EQ VAS. EQ VAS has a minimum of 0 and a maximum of 100. Higher scores mean a better health condition.

  13. Sleep Quality: Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Month 1

    Time frame: Baseline and Month 1

    Sleep quality is assessed by PSQI and compared with baseline PSQI score. PSQI score has a minimum of 0 and maximum of 21. Higher scores mean a worse sleep quality.

  14. Sleep Quality: Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Month 3

    Time frame: Baseline and Month 3

    Sleep quality is assessed by PSQI and compared with baseline PSQI score. PSQI score has a minimum of 0 and maximum of 21. Higher scores mean a worse sleep quality.

  15. Sleep Quality: Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Month 6

    Time frame: Baseline and Month 6

    Sleep quality is assessed by PSQI and compared with baseline PSQI score. PSQI score has a minimum of 0 and maximum of 21. Higher scores mean a worse sleep quality.

  16. Global impression: Change From Baseline in Patient's Global Impression of Change (PGIC) at Month 1

    Time frame: Baseline and Month 1

    The change of overall health condition is assessed by PGIC and compared with baseline PGIC score. PGIC score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.

  17. Global impression: Change From Baseline in Patient's Global Impression of Change (PGIC) at Month 3

    Time frame: Baseline and Month 3

    The change of overall health condition is assessed by PGIC and compared with baseline PGIC score. PGIC score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.

  18. Global impression: Change From Baseline in Patient's Global Impression of Change (PGIC) at Month 6

    Time frame: Baseline and Month 6

    The change of overall health condition is assessed by PGIC and compared with baseline PGIC score. PGIC score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.

  19. Global impression: Change From Baseline in Clinical Global Impressions-Improvement (CGI-I) at Month 1

    Time frame: Baseline and Month 1

    The change of overall health condition is assessed by physicians using the CGI-I and compared with baseline CGI-I score. CGI-I score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.

  20. Global impression: Change From Baseline in Clinical Global Impressions-Improvement (CGI-I) at Month 3

    Time frame: Baseline and Month 3

    The change of overall health condition is assessed by physicians using the CGI-I and compared with baseline CGI-I score. CGI-I score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.

  21. Global impression: Change From Baseline in Clinical Global Impressions-Improvement (CGI-I) at Month 6

    Time frame: Baseline and Month 6

    The change of overall health condition is assessed by physicians using the CGI-I and compared with baseline CGI-I score. CGI-I score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.

Study contacts

Contact information is provided by the study sponsor or research team.

Yang Lu, MD

CONTACT

[email protected]

18600391166 ext. +86

Sponsors and collaborators

Lead sponsor

Beijing Tsinghua Chang Gung Hospital

Other

Registry information

Official study title

Precise Management System (PreMaSy) of Chronic Intractable Pain Based on a Remote and Wireless Spinal Cord Stimulation System

Acronym: PreMaSy

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 9, 2023
Registry last updated
Mar 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.